🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseGLP-1 hepatoprotection — direct vs indirect mechanisms

GLP-1 hepatoprotection — direct vs indirect mechanisms

MASHdoc_SA Sun, Jun 7, 2026 at 4:05 PM 16 replies 402 viewsPage 1 of 4
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Jun 7, 2026 at 4:05 PM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

What I am trying to establish is which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. Tell me what I have not thought of.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
49 19TirzTom, TrialTracker_MD, JennaRN and 46 others
Reply Quote Save Share Report
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Jun 7, 2026 at 4:07 PM#2
MASHdoc_SA said:
The mechanism is more central than most summaries suggest.

Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%), creating a depot effect with a ~168-hour half-life enabling weekly dosing[1].

Tirzepatide is a dual GIP/GLP-1R agonist with higher GIP affinity (5:1 GIP:GLP-1 potency ratio). The GIP component may enhance beta-cell function and adipocyte lipid metabolism beyond what GLP-1 alone achieves.

For the pharmacology, the pharmacology explains the clinical differences between these agents.

References:
[1] Lau J, et al. J Med Chem. 2015;58(18):7370-7380.
Last edited: Jun 7, 2026 at 5:07 PM
48 18KarenAZ_mom, zoe_NC, Dr.ObesityLA and 45 others
Reply Quote Save Share Report
mike_nyc
VIP Member
5,678
21,345
Nov 2023
New York
Online
Jun 7, 2026 at 4:09 PM#3
MASHdoc_SA said:
The mechanism is more central than most summaries suggest.

This is where I part company with the consensus forming above. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

47 17Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 44 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Jun 7, 2026 at 4:11 PM#4
mike_nyc said:
The pharmacokinetics explain nearly every practical question asked here.

Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36). Three key modifications enable its pharmacokinetic profile:

  1. Aib8 substitution: DPP-4 resistance (prevents enzymatic degradation)
  2. Arg34 substitution: improved chemical stability
  3. C18 fatty diacid at Lys26: albumin binding → long half-life

These three modifications transform a peptide with a 2-minute half-life (native GLP-1) into one with a 168-hour half-life (semaglutide). A masterclass in peptide engineering.

46 16roxy_nash, tony_orlando, Dr.NephBHM_UK and 43 others
Reply Quote Save Share Report
mona_PHX
Member
189
890
Dec 2024
Phoenix, AZ
Jun 7, 2026 at 4:23 PM#5
Dr.ObesityLA said:
Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%),…

Same pattern here, and in the same order.

45 15MariaRD, AussieAnna, BethLabQueen and 42 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
MASH resolution without worsening fibrosis — endpoint analysis11 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register